This study, published in PLOS ONE, explores how SHBG levels relate to the risk of metabolic and cardiovascular problems in pregnant women, especially those who are obese either before pregnancy, during pregnancy, or both.
What Did the Researchers Do?
The scientists enrolled 291 Caucasian pregnant women in Spain. They grouped them based on their weight before and during pregnancy:
- Normal weight
- Obese before pregnancy
- Obese during pregnancy (but not before)
- Obese both before and during pregnancy (the “double” obesity group)
They measured SHBG in the blood, along with many other markers related to metabolic and cardiovascular health, including:
- C-reactive protein (CRP) (inflammation marker)
- Blood pressure (systolic and diastolic)
- Blood sugar and hemoglobin A1c (blood sugar control)
- Insulin and C-peptide (insulin production)
- Triglycerides (type of fat in the blood)
- HMW adiponectin (a protein involved in regulating glucose and fatty acid breakdown)
- Testosterone and estradiol (sex hormones)
They also collected information about the babies: birth weight, length, head circumference, and placental weight.
Key Results
- Women who were obese before and during pregnancy (double obese) had significantly lower SHBG levels than women with normal weight.
- Lower SHBG levels were strongly linked to a worse cardiometabolic profile: higher blood pressure, higher CRP (more inflammation), higher blood sugar, higher insulin resistance, higher fat in the blood, and lower HMW adiponectin.
- These associations were most prominent in the double obese group. In women who were only obese in one category (either before or during pregnancy), most of these links were weaker or not present.
- After accounting for other factors like age, education, body mass index (BMI), smoking, metabolic and hormonal status, SHBG still independently predicted higher CRP and blood pressure in the double obese women.
- SHBG levels had negative associations with birth weight and other newborn measurements, but these did not remain significant after adjusting for confounders.
Understanding the Connections
SHBG is recognized to decrease with obesity and increase with weight loss. When SHBG is low, more active sex hormones may be available, which can disrupt normal fat storage and use, and contribute to insulin resistance and inflammation—key aspects of metabolic syndrome and cardiovascular risk. Prior research in non-pregnant adults and in those with polycystic ovarian syndrome has shown similar links between low SHBG and negative metabolic outcomes.
Pregnancy itself alters hormone levels—SHBG typically rises, particularly in the mid-second trimester. However, in women who are obese both before and during pregnancy, this rise is blunted, which the study suggests is due to persistent insulin resistance and inflammation.
Strengths and Limitations
The study’s strengths include a relatively large and well-characterized group of pregnant women, with high-quality, detailed measurements. However, there were limitations:
- The study looked only at Caucasian women in Spain—so the findings may not be universal.
- Physical activity and some socioeconomic factors were not measured.
- The cross-sectional design means we cannot say for certain whether low SHBG causes these problems, or is simply a marker of risk.
- Long-term impacts on mothers and children were not assessed.
Technical and Granular Summary
This PLOS ONE study demonstrates that in pregnant women, especially those with both pregestational and gestational obesity, low circulating SHBG is independently associated with multiple markers of adverse cardiometabolic risk, including elevated CRP and blood pressure, as well as metabolic derangements such as insulin resistance and hypertriglyceridemia. These associations persist after adjustment for BMI and a spectrum of metabolic and endocrine confounders, underscoring the potential of SHBG to serve as an integrative biomarker that encapsulates the multifactorial risk state present in these women. Although SHBG shows statistical correlations with several anthropometric neonatal markers, these are not robust to adjustment for maternal and perinatal factors, highlighting possible complexity in mother-offspring risk transmission pathways. Methodologically, the results are strengthened by multivariate modeling, but are limited by the observational, cross-sectional design and absence of longitudinal maternal or offspring outcome data. Holistically, the study points to SHBG not only as a sensor of metabolic stress in the context of combined pregestational and gestational obesity but also as a potential early-warning marker for future maternal cardiovascular morbidity, pending further confirmatory and mechanistic work.
.svg)
.avif)